Sandra P. D’Angelo

19.1k citations
193 papers · 7.9k · 5 hit papers · h-index 38

Impact in

  • Oncology top 0.2%
    • Cancer Immunotherapy and Biomarkers
    • CAR-T cell therapy research
    • Polyomavirus and related diseases
    • Vascular Tumors and Angiosarcomas
    • Sarcoma Diagnosis and Treatment
    • Lung Cancer Treatments and Mutations

Papers in

    • CAR-T cell therapy research 56
    • Cancer Immunotherapy and Biomarkers 36
    • Polyomavirus and related diseases 28
    • Vascular Tumors and Angiosarcomas 24
    • Sarcoma Diagnosis and Treatment 59

Sandra P. D’Angelo

184 papers receiving 7.8k citations

Sandra P. D’Angelo's Hit Papers

Nivolumab with or without ipilimumab treatment for metastatic sarcoma (Alliance A091401): two open-label, non-comparative, randomised, phase 2 trials 2018 · 509 citations
5090+4+9Years since publication250500750

Peers

Sandra P. D’Angelo
Comparison fields: 5 of 113
  • Oncology 5.1k
  • Pulmonary and Respiratory Medicine 3.0k
  • Immunology 1.2k
  • Gastroenterology 214
  • Pathology and Forensic Medicine 612
Replace Neil H. Segal with:
Neil H. Segal United States
Stéphane Champiat France
Craig Devoe United States
Evan J. Lipson United States
Valerie S. Barta United States
S. Pilotti Italy
Jonathan E. Rosenberg United States
Mark M. Awad United States
Leah Haworth United States
Shumei Kato United States
Sandra P. D’Angelo relative to Neil H. Segal United States Neil H. Segal's profile →
Citations per field
00.5×1.5×1.8×
Neil H. Segal · 1×
Citations per year

Countries citing papers authored by Sandra P. D’Angelo

Since Specialization
Citations

This map shows the geographic impact of Sandra P. D’Angelo's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Sandra P. D’Angelo with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Sandra P. D’Angelo more than expected).

Fields of papers citing papers by Sandra P. D’Angelo

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Sandra P. D’Angelo. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Sandra P. D’Angelo. The network helps show where Sandra P. D’Angelo may publish in the future.

Co-authors

The 25 scholars most cited alongside Sandra P. D’Angelo, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.

Border = papers with Sandra P. D’Angelo Line = papers co-authored together Sandra P. D’Angelo links everyone, so they are left out of the graph.

All Works

20 of 20 papers shown

Showing the 20 most-cited of 193 papers — load more, or switch the sort, to bring in the rest.

#Work
1
Avelumab in patients with chemotherapy-refractory metastatic Merkel cell carcinoma: a multicentre, single-group, open-label, phase 2 trial
Hit paper breakdown →
2016940
2
Immune-Related Adverse Events, Need for Systemic Immunosuppression, and Effects on Survival and Time to Treatment Failure in Patients With Melanoma Treated With Ipilimumab at Memorial Sloan Kettering Cancer Center
Hit paper breakdown →
2015815
3
Nivolumab with or without ipilimumab treatment for metastatic sarcoma (Alliance A091401): two open-label, non-comparative, randomised, phase 2 trials
Hit paper breakdown →
2018509
4
Molecular Epidemiology of EGFR and KRAS Mutations in 3,026 Lung Adenocarcinomas: Higher Susceptibility of Women to Smoking-Related KRAS -Mutant Cancers
Hit paper breakdown →
2012505
5
Phase II Trial of the CDK4 Inhibitor PD0332991 in Patients With Advanced CDK4 -Amplified Well-Differentiated or Dedifferentiated Liposarcoma
Hit paper breakdown →
2013321
6 2018271
7 2014241
8 2018238
9 2016229
10 2011218
11 2016216
12 2016150
13 2013146
14 2012142
15 2020137
16 2014122
17 2013117
18 2005105
19 2010102
20 2016100

About Sandra P. D’Angelo

Sandra P. D’Angelo is a scholar working on Oncology, Pulmonary and Respiratory Medicine, Immunology, Molecular Biology and Ecology, having authored 193 papers that have together received 7.9k indexed citations. Recurring topics across this work include Sarcoma Diagnosis and Treatment (59 papers), CAR-T cell therapy research (56 papers), Immunotherapy and Immune Responses (37 papers), Cancer Immunotherapy and Biomarkers (36 papers), Polyomavirus and related diseases (28 papers), Vascular Tumors and Angiosarcomas (24 papers), Bacteriophages and microbial interactions (16 papers) and Plant Virus Research Studies (15 papers). The work is most often cited by research in Oncology (5.1k citations), Pulmonary and Respiratory Medicine (3.0k citations), Immunology (1.2k citations), Gastroenterology (214 citations) and Pathology and Forensic Medicine (612 citations). Sandra P. D’Angelo has collaborated with scholars based in United States, France and Germany. Frequent co-authors include William D. Tap, Mark A. Dickson, Gary K. Schwartz, Cristina R. Antonescu, Richard D. Carvajal, Mark G. Kris, Célèste Lebbé, Mary Louise Keohan, Mrinal M. Gounder and Patrick Terheyden. Their work appears in journals such as Journal of Clinical Oncology, Annals of Oncology, Journal for ImmunoTherapy of Cancer, Sarcoma and Clinical Cancer Research.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact